Chinese biotech company HitGen Inc (688222.SH) said on Saturday that it has extended the previous drug discovery research collaboration to identify small molecule leads against targets specified by Morphic Therapeutic.
Pursuant to the extended agreement, HitGen will use its DNA-encoded library (DEL) technology platform based on the design, synthesis and interrogation and selection to discover ligands for targets of interest to Morphic.
In conjunction with the collaboration, Morphic will pay an assignment fee to HitGen in exchange for exclusive development and commercialization rights to compounds that achieve the criteria of the collaboration.
Additionally, HitGen's industry-leading DNA-encoded library (DEL) technology platform includes over 400bn encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds.
AstraZeneca reports positive Phase III data for Imfinzi and Imjudo in liver cancer
Thermo Fisher Scientific unveils CHOvantage GS Kit to speed biologics development
Frontier Medicines licenses FMC-220 oncology programme to LG Chem in global deal
NJ Bio and Aji Bio-Pharma partner to strengthen support for ADC development
Alltrna granted approval for first-in-human clinical trial of AP003
Lilly to acquire Centessa Pharmaceuticals for up to USD47 per share
Natera study shows Signatera MRD may help select breast cancer patients for non-surgical management
AstraZeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia
Galapagos and Gilead expand collaboration to advance T cell engager programme
Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
Hengrui Pharma and Braveheart Bio report positive Phase 2 results for HRS/BHB-1893 in oHCM
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
Fusion Antibodies signs GBP250,000 IP transfer deal with Finn Therapeutics